Israel Englander Vertex Pharmaceuticals Inc Put Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $22.6 Million - $24.9 Million	-49,200 Reduced 82.83%	10,200 $4.74 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $8.13 Million - $10.1 Million	20,700 Added 53.49%	59,400 $27.8 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $27.4 Million - $29.9 Million	-67,100 Reduced 63.42%	38,700 $16.2 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $13.2 Million - $15.9 Million	38,600 Added 57.44%	105,800 $43 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $21.7 Million - $24.3 Million	-69,100 Reduced 50.7%	67,200 $23.6 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $14.8 Million - $16.8 Million	52,100 Added 61.88%	136,300 $42.9 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $8.49 Million - $9.55 Million	29,700 Added 54.5%	84,200 $24.3 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $20.6 Million - $23 Million	-75,400 Reduced 58.04%	54,500 $15.8 Million

1,721

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.